WallStSmart
RCUS

Arcus Biosciences Inc

NYSE: RCUS · HEALTHCARE · BIOTECHNOLOGY

$24.13
-2.70% today

Updated 2026-04-29

Market cap
$3.03B
P/E ratio
P/S ratio
12.27x
EPS (TTM)
$-3.29
Dividend yield
52W range
$7 – $29
Volume
1.3M

Arcus Biosciences Inc (RCUS) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+24.3%
Last 4 quarters
Revenue YoY growth
+26.9%
Most recent quarter
EPS YoY growth
+13.6%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+1.0%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+9.1%
2025-10-28
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-25$-0.89+19.1%$20.19$19.54-3.2%
2025-10-28$-1.27+0.8%$18.60$20.29+9.1%
2025-08-06$0.00+100.0%$9.55$9.28-2.8%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-1.10$-0.89+19.1%$33.00M+26.9%
2025-09-30$-1.28$-1.27+0.8%$26.00M-45.8%
2025-06-30$-1.12$0.00+100.0%$160.00M+310.3%
2025-03-31$-0.93$-1.14-22.6%$28.00M-80.7%
2024-12-31$-1.20$-1.03+14.4%$26.00M-16.1%
2024-09-30$-1.06$-1.00+5.7%$48.00M+50.0%
2024-06-30$-1.10$-1.02+7.3%$39.00M+34.5%
2024-03-31$-0.95$-0.05+94.7%$145.00M
2023-12-31$-1.02$-1.08-5.9%$31.00M
2023-09-30$-1.13$-0.94+16.8%$32.00M
2023-06-30$-1.10$-1.04+5.5%$29.00M

Frequently asked questions

Has Arcus Biosciences Inc beaten earnings estimates?
Arcus Biosciences Inc has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +24.3% over the last 4 quarters.
How does RCUS stock react to earnings?
RCUS stock has moved an average of +1.0% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Arcus Biosciences Inc's revenue growth rate?
Arcus Biosciences Inc reported year-over-year revenue growth of +26.9% in its most recent quarter, with EPS growing +13.6% year-over-year.